Dr. Longle Ma is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on preparation and prosecution of patents in technical areas spanning from chemistry and pharmaceuticals to biotechnology. Longle assists clients in strategical creation and management of patent portfolios and counsels clients on freedom-to-operate and patentability analyses.
Prior to joining the firm, Longle was an associate and a patent agent at a Boston-based law firm where he advised clients of various stages on intellectual property matters in the field of small molecule, nucleic acid, and peptide therapeutics, organic chemistry, specialty materials, and biotechnology. Longle was a postdoctoral fellow at Massachusetts General Hospital/Harvard Medical School working on radiochemistry and development of radiotracers for medical imaging. He received his Ph.D. from Rutgers University where his graduate research was focused on the development of C–H bond functionalization methodology and synthesis of natural products.
Dr. Longle Ma is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on preparation and prosecution of patents in technical areas spanning from chemistry and pharmaceuticals to biotechnology. Longle assists clients in strategical creation and management of patent portfolios and counsels clients on freedom-to-operate and patentability analyses.
Prior to joining the firm, Longle was an associate and a patent agent at a Boston-based law firm where he advised clients of various stages on intellectual property matters in the field of small molecule, nucleic acid, and peptide therapeutics, organic chemistry, specialty materials, and biotechnology. Longle was a postdoctoral fellow at Massachusetts General Hospital/Harvard Medical School working on radiochemistry and development of radiotracers for medical imaging. He received his Ph.D. from Rutgers University where his graduate research was focused on the development of C–H bond functionalization methodology and synthesis of natural products.
- J.D., Boston College Law School, 2023
Cum Laude
- Ph.D., Organic Chemistry, Rutgers University, 2015
- B.S., Chemistry, Nankai University, 2010
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
- J.D., Boston College Law School, 2023
Cum Laude
- Ph.D., Organic Chemistry, Rutgers University, 2015
- B.S., Chemistry, Nankai University, 2010
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Select Publications
- Co-author with A. Paul, H. S. Chandak, and D. Seidel, “Redox-Annulations of Cyclic Amines with ortho-Cyanomethylbenzaldehydes,” 22 Org. Lett. 976-980, 2020
- Co-author with W. Chen, A. Paul, and D. Seidel, “Direct α-C–H Bond Functionalization of Unprotected Cyclic Amines,” 10 Nat. Chem. 165-169, 2018
- Co-author with M. S. Placzek, J. M. Hooker, N. Vasdev, and S. Liang, “[11C]Cyanation of Arylboronic Acids in Aqueous Solutions,” 53 Chem. Commun. 6597–6600, 2017
- Co-author with H. S. Krishnan, N. Vasdev, and S. H. Liang, “18F-Labeling of Sensitive Biomolecules for Positron Emission Tomography,” 23 Chem. Eur. J. 15553–15577, 2017
- Co-author with A. Paul, M. Brugst, and D. Seidel, “Redox-Neutral Aromatization of Cyclic Amines: Mechanistic Insights and Harnessing of Reactive Intermediates for Amine α- and β-C–H Functionalization,” 22 Chem. Eur. J. 18179–18189, 2016
- Co-author with W. Chen and D. Seidel, “Redox-Neutral α-Cyanation of Amines,” 134 J. Am. Chem. Soc. 15305–15308, 2012
Select Publications
- Co-author with A. Paul, H. S. Chandak, and D. Seidel, “Redox-Annulations of Cyclic Amines with ortho-Cyanomethylbenzaldehydes,” 22 Org. Lett. 976-980, 2020
- Co-author with W. Chen, A. Paul, and D. Seidel, “Direct α-C–H Bond Functionalization of Unprotected Cyclic Amines,” 10 Nat. Chem. 165-169, 2018
- Co-author with M. S. Placzek, J. M. Hooker, N. Vasdev, and S. Liang, “[11C]Cyanation of Arylboronic Acids in Aqueous Solutions,” 53 Chem. Commun. 6597–6600, 2017
- Co-author with H. S. Krishnan, N. Vasdev, and S. H. Liang, “18F-Labeling of Sensitive Biomolecules for Positron Emission Tomography,” 23 Chem. Eur. J. 15553–15577, 2017
- Co-author with A. Paul, M. Brugst, and D. Seidel, “Redox-Neutral Aromatization of Cyclic Amines: Mechanistic Insights and Harnessing of Reactive Intermediates for Amine α- and β-C–H Functionalization,” 22 Chem. Eur. J. 18179–18189, 2016
- Co-author with W. Chen and D. Seidel, “Redox-Neutral α-Cyanation of Amines,” 134 J. Am. Chem. Soc. 15305–15308, 2012
Therapeutics and Drug Discovery
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Organic chemistry
- Organometallics
- Polymorph
- Process chemistry
Miscellaneous
- Formulations
Therapeutics and Drug Discovery
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Organic chemistry
- Organometallics
- Polymorph
- Process chemistry
Miscellaneous
- Formulations
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
- Privacy Policy
- Terms of Use
- Accessibility